

# Vasilios G. Athyros

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/2817635/vasilios-g-athyros-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

304  
papers

10,039  
citations

53  
h-index

88  
g-index

387  
ext. papers

11,490  
ext. citations

3.8  
avg, IF

6.04  
L-index

#	Paper	IF	Citations
304	A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine. <i>Angiology</i> , <b>2022</b> , 73, 87	2.1	8
303	Serum adipokine levels in patients with type 1 diabetes are associated with degree of obesity but only resistin is independently associated with atherosclerosis markers. <i>Hormones</i> , <b>2021</b> , 1	3.1	0
302	Statins and Non-Alcoholic Fatty Liver Disease Progression: Further Comments. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 673-674	3.3	
301	Multifactorial treatment of diabetic patients with cardiovascular disease to maximize results. <i>Journal of Diabetes and Its Complications</i> , <b>2021</b> , 35, 107904	3.2	1
300	Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia. <i>Expert Review of Cardiovascular Therapy</i> , <b>2021</b> , 19, 575-580	2.5	1
299	Ertugliflozin + metformin as a treatment option for type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2105-2111	4	
298	Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. <i>Current Vascular Pharmacology</i> , <b>2021</b> , 19, 572-581	3.3	6
297	Clinical benefit of statin treatment on patients with non-alcoholic fatty liver disease or steatohepatitis: RE: Fatima K, Moeed A, Waqar E, Atif AR, Kamran A, Rizvi H, Suri NF, Haider H, Shuja SH, Khalid M, Minhas AMK. Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: a systematic review and meta-analysis. <i>Clin Res Hepatol</i>	2.4	
296	Treatment strategies for hypertension in patients with type 1 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 1241-1252; <i>Hepatology and Gastroenterology</i> , <b>2021</b> , 46, 101842	4	5
295	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. <i>Current Vascular Pharmacology</i> , <b>2020</b> , 18, 172-181	3.3	24
294	Efficacy and safety of statin use in children and adolescents with familial hypercholesterolaemia: a systematic review and meta-analysis of randomized-controlled trials. <i>Endocrine</i> , <b>2020</b> , 69, 249-261	4	9
293	Dysmetabolic Iron Overload in Metabolic Syndrome. <i>Current Pharmaceutical Design</i> , <b>2020</b> , 26, 1019-1024	3.3	12
292	Cholesterol levels of high-density lipoprotein (HDL-C), APOB/APOA1 ratio and cardiovascular risk in patients with familial hypercholesterolemia (FH): Data from the HELLAS-FH registry. <i>Atherosclerosis</i> , <b>2020</b> , 315, e39-e40	3.1	
291	Effect of high and low dose of rosuvastatin on fatty liver disease and adipokines in patients with nonalcoholic fatty liver disease. <i>Atherosclerosis</i> , <b>2020</b> , 315, e98-e99	3.1	
290	Clinical characteristics of patients with familial hypercholesterolemia: Data from the HELLAS-FH registry. <i>Atherosclerosis</i> , <b>2020</b> , 315, e210-e211	3.1	
289	NAFLD and Statins. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 3052-3053	4	1
288	Non-alcoholic steatohepatitis and type 2 diabetes mellitus: the effects of weight loss versus drug treatment. <i>Current Medical Research and Opinion</i> , <b>2019</b> , 35, 1305-1306	2.5	1

287	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. <i>Expert Opinion on Drug Safety</i> , <b>2019</b> , 18, 241-251	4.1	3
286	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. <i>Current Vascular Pharmacology</i> , <b>2019</b> , 17, 425-428	3.3	4
285	Statin use in patients with diabetes: one drug, multiple benefits. <i>Expert Review of Cardiovascular Therapy</i> , <b>2019</b> , 17, 839-840	2.5	2
284	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. <i>Journal of Clinical Hypertension</i> , <b>2019</b> , 21, 1578-1579	2.3	0
283	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 589-591	2.3	1
282	Subclinical target organ damage in primary aldosteronism: resistant to spironolactone therapy?. <i>Journal of Hypertension</i> , <b>2018</b> , 36, 701	1.9	2
281	Carotid intima-media thickness as a target-organ damage and treatment-target: Need for a major revision?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 255-257	2.3	3
280	Diabetes and lipid metabolism. <i>Hormones</i> , <b>2018</b> , 17, 61-67	3.1	81
279	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 634-636	2.3	2
278	The potential role of statins in treating liver disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2018</b> , 12, 331-339	4.2	10
277	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 469-471	2.3	2
276	Lipid-lowering treatment in peripheral artery disease. <i>Current Opinion in Pharmacology</i> , <b>2018</b> , 39, 19-26	5.1	12
275	Contrast-induced acute kidney injury: beware of the risk after coronary angiography. <i>Expert Review of Cardiovascular Therapy</i> , <b>2018</b> , 16, 73	2.5	2
274	Dietary management of dyslipidaemias. Is there any evidence for cardiovascular benefit?. <i>Maturitas</i> , <b>2018</b> , 108, 45-52	5	16
273	The effect of antidiabetic medications on the cardiovascular system: a critical appraisal of current data. <i>Hormones</i> , <b>2018</b> , 17, 83-95	3.1	2
272	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. <i>Journal of Clinical Hypertension</i> , <b>2018</b> , 20, 942-948	2.3	5
271	Statins and substantially increased ALT values at baseline. <i>Cardiovascular Therapeutics</i> , <b>2018</b> , 36, e12444	3.3	3
270	Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 1879-1886	3.3	11

269	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 4587-4592	3.3	18
268	Boosting the Limited Use of Mineralocorticoid Receptor Antagonists Through New Agents for Hyperkalemia. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 5542-5547	3.3	0
267	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 130-142	3.3	36
266	Nonalcoholic Fatty Liver Disease vs. Nonalcoholic Steatohepatitis: Pathological and Clinical Implications. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 214-218	3.3	10
265	The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 254-268	3.3	8
264	Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 269-275	3.3	9
263	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 246-253	3.3	49
262	Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 393-400	3.3	7
261	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. <i>Current Pharmaceutical Design</i> , <b>2018</b> , 24, 3638-3646	3.3	7
260	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. <i>Open Cardiovascular Medicine Journal</i> , <b>2018</b> , 12, 29-40	0.7	15
259	Characteristics and management of 1093 patients with clinical diagnosis of familial hypercholesterolemia in Greece: Data from the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Atherosclerosis</i> , <b>2018</b> , 277, 308-313	3.1	15
258	Antihypertensive therapy in acute ischemic stroke: where do we stand?. <i>Journal of Human Hypertension</i> , <b>2018</b> , 32, 799-807	2.6	5
257	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 71, 17-32	12.7	152
256	Semaglutide, lipid-lowering drugs, and NAFLD. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 329-330	18.1	10
255	Vildagliptin: any effect on non-alcoholic fatty liver disease and serum uric acid? Re: Shelbaya S, Rakha S. Effectiveness and safety of vildagliptin and vildagliptin add-on to metformin in real-world settings in Egypt - results from the GUARD study. <i>Curr Med Res Opin</i> 2017;33:797-801. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 2261-2262	2.5	
254	Letter to the editor: Treating nonalcoholic fatty liver disease with statins. Are all statins equal?. <i>American Journal of Physiology - Renal Physiology</i> , <b>2017</b> , 312, G681-G682	5.1	3
253	Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. <i>Nutrition Reviews</i> , <b>2017</b> , 75, 307-326	6.4	183
252	Response letter: Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 66, e6	12.7	1

251	An insight into familial hypercholesterolemia in Greece: rationale and design of the Hellenic Familial Hypercholesterolemia Registry (HELLAS-FH). <i>Hormones</i> , <b>2017</b> , 16, 306-312	3.1	6
250	Arterial stiffness correlates with the severity of hepatic fibrosis in patients with nonalcoholic fatty liver disease. <i>Atherosclerosis</i> , <b>2017</b> , 263, e197	3.1	2
249	The effect of SGLT2 inhibitors on cardiovascular events and renal function. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1251-1261	3.8	9
248	Mortality reduction in patients treated with intensive lipid therapy vs usual care. Re: Zhao XQ, Phan BA, Davis J et al. Mortality reduction in patients treated with long-term intensive lipid therapy: 25-year follow-up of the Familial Atherosclerosis Treatment Study-Observational Study. <i>J Clin Lipidol</i> . 2016;10(5):1091-1097. <i>Journal of Clinical Lipidology</i> , <b>2017</b> , 11, 306-307	4.9	
247	Statins and non-alcoholic steatohepatitis. <i>Metabolism: Clinical and Experimental</i> , <b>2017</b> , 66, e1-e2	12.7	5
246	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. <i>Current Pharmaceutical Design</i> , <b>2017</b> , 23, 1477-1483	3.3	5
245	Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. <i>Open Hypertension Journal</i> , <b>2017</b> , 9, 1-5	0.8	
244	Statins and non-alcoholic steatohepatitis. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 241-2	13.4	7
243	Hypertrophic Mesenteric Adipose Tissue May Play a Role in Atherogenesis in Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , <b>2016</b> , 22, 2206-12	4.5	6
242	Cardiovascular effects of sodium-glucose cotransporter 2 inhibitors: multiple actions. <i>Current Medical Research and Opinion</i> , <b>2016</b> , 32, 1513-4	2.5	13
241	Statins for Improving Myocardial Perfusion in Patients With Nonalcoholic Fatty Liver Disease Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , <b>2016</b> , 117, 311-2	3	1
240	Is Targeting microRNAs the Philosopher's Stone for Vascular Disease?. <i>Current Vascular Pharmacology</i> , <b>2016</b> , 14, 88-97	3.3	6
239	Exploring the Management of Statin Intolerant Patients: 2016 and Beyond. <i>Current Vascular Pharmacology</i> , <b>2016</b> , 14, 523-533	3.3	11
238	Is There an Association Between Carotid-Femoral Pulse Wave Velocity and Coronary Heart Disease in Patients with Coronary Artery Disease: A Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , <b>2016</b> , 10, 64-8	0.7	2
237	Adherence to statin treatment: an important issue in clinical practice. <i>Current Medical Research and Opinion</i> , <b>2016</b> , 32, 1639-1640	2.5	1
236	Off target effects of statins shape total mortality?. <i>Journal of Drug Assessment</i> , <b>2016</b> , 5, 4-5	1.5	1
235	Statins, renal function and homocysteine. <i>Pharmacological Reports</i> , <b>2016</b> , 68, 1093	3.9	
234	Canagliflozin and Hypertension: Is It the Optimal Choice for All Hypertensive Patients?. <i>Journal of Clinical Hypertension</i> , <b>2016</b> , 18, 1073	2.3	3

233	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. <i>Clinical Lipidology</i> , <b>2016</b> , 11, 2-5		3
232	Treatment options for dyslipidemia in chronic kidney disease and for protection from contrast-induced nephropathy. <i>Expert Review of Cardiovascular Therapy</i> , <b>2015</b> , 13, 1059-66	2.5	4
231	Nonalcoholic fatty liver disease and statins. <i>Metabolism: Clinical and Experimental</i> , <b>2015</b> , 64, 1215-23	12.7	47
230	The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. <i>European Heart Journal</i> , <b>2015</b> , 36, 1536-46	9.5	88
229	Metabolic syndrome: Different definitions and gender-specific associations with cardiovascular risk factors. <i>Diabetes and Vascular Disease Research</i> , <b>2015</b> , 12, 471-2	3.3	3
228	Contrast-Induced Nephropathy: An "All or None" Phenomenon?. <i>Angiology</i> , <b>2015</b> , 66, 508-13	2.1	81
227	Statin therapy and cardiovascular outcomes after coronary revascularization in the elderly. <i>Atherosclerosis</i> , <b>2015</b> , 238, 182-4	3.1	0
226	High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus. <i>Journal of Diabetes and Its Complications</i> , <b>2015</b> , 29, 142-5	3.2	12
225	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 6820-34	5.6	91
224	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 7860-8	5.6	97
223	Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis. <i>Review of Diabetic Studies</i> , <b>2015</b> , 12, 110-8	3.6	106
222	Statins can improve proteinuria and glomerular filtration rate loss in chronic kidney disease patients, further reducing cardiovascular risk. Fact or fiction?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 1449-61	4	33
221	Hyperuricemia as a risk factor for cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , <b>2015</b> , 13, 19-20	2.5	18
220	Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment. <i>Current Vascular Pharmacology</i> , <b>2015</b> , 13, 788-800	3.3	13
219	Treating Heart Failure with Preserved Ejection Fraction Related to Arterial Stiffness. Can we Kill Two Birds With One Stone?. <i>Current Vascular Pharmacology</i> , <b>2015</b> , 13, 368-80	3.3	8
218	Treating heart failure with preserved ejection fraction: statins could make the difference. <i>Angiology</i> , <b>2014</b> , 65, 328-9	2.1	1
217	Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. <i>Nature Reviews Cardiology</i> , <b>2014</b> , 11, 72-4	14.8	13
216	Therapy: Caloric and fat intake in statin users. <i>Nature Reviews Endocrinology</i> , <b>2014</b> , 10, 450-1	15.2	1

215	Peripheral artery disease in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , <b>2014</b> , 28, 912	3.2	3
214	Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review. <i>Angiology</i> , <b>2014</b> , 65, 284-93	2.1	20
213	Lipoprotein-associated phospholipase A2 and arterial stiffness evaluation in patients with inflammatory bowel diseases. <i>Journal of Crohn's and Colitis</i> , <b>2014</b> , 8, 936-44	1.5	15
212	The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 362-3	18.1	9
211	Effects of renin-angiotensin-aldosterone system inhibitors and beta-blockers on markers of arterial stiffness. <i>Journal of the American Society of Hypertension</i> , <b>2014</b> , 8, 74-82		64
210	Priority Paper Evaluation: Are antibodies against PCSK9 the statins of the 21st century?. <i>Clinical Lipidology</i> , <b>2014</b> , 9, 141-144		
209	Acute kidney injury: Short-term statin therapy for prevention of contrast-induced AKI. <i>Nature Reviews Nephrology</i> , <b>2014</b> , 10, 8-9	14.9	21
208	Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit. <i>Expert Review of Cardiovascular Therapy</i> , <b>2014</b> , 12, 295-6	2.5	1
207	Beneficial effects of high atorvastatin dose reloading prior to percutaneous coronary intervention. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 55	2.5	
206	Statin-fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 57-8	2.5	2
205	Should we expand the concept of coronary heart disease equivalents?. <i>Current Opinion in Cardiology</i> , <b>2014</b> , 29, 389-95	2.1	26
204	Is there an association between inflammatory bowel diseases and carotid intima-media thickness? Preliminary data. <i>Angiology</i> , <b>2014</b> , 65, 543-50	2.1	27
203	Subclinical Cushing's syndrome and cardiovascular disease. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 361	18.1	6
202	High-density lipoprotein, vascular risk, cancer and infection: a case of quantity and quality?. <i>Current Medicinal Chemistry</i> , <b>2014</b> , 21, 2917-26	4.3	28
201	The role of statins in the treatment of type 2 diabetes mellitus: an update. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 3665-74	3.3	31
200	Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure. <i>Current Pharmaceutical Design</i> , <b>2014</b> , 20, 6306-13	3.3	5
199	Effect of rosuvastatin on non-alcoholic steatohepatitis in patients with metabolic syndrome and hypercholesterolaemia: a preliminary report. <i>Current Vascular Pharmacology</i> , <b>2014</b> , 12, 505-11	3.3	24
198	Characteristics other than the diagnostic criteria associated with metabolic syndrome: an overview. <i>Current Vascular Pharmacology</i> , <b>2014</b> , 12, 627-41	3.3	36

197	Comparative Effect of Atorvastatin and Rosuvastatin on 25-hydroxy-Vitamin D Levels in Non-diabetic Patients with Dyslipidaemia: A Prospective Randomized Open-label Pilot Study. <i>Open Cardiovascular Medicine Journal</i> , <b>2014</b> , 8, 55-60	0.7	14
196	11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?. <i>Metabolism: Clinical and Experimental</i> , <b>2013</b> , 62, 21-33	12.7	66
195	Alcohol consumption and the heart. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 4319	3.2	
194	Beliefs and attitudes regarding cardiovascular disease risk factors: a health survey in 10,141 Greek men and women (2006-2012). <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 4847-9	3.2	6
193	Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity. <i>Journal of Clinical Lipidology</i> , <b>2013</b> , 7, 88	4.9	2
192	Comment to "atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor- $\alpha$ -lowering property". <i>Digestive and Liver Disease</i> , <b>2013</b> , 45, 82-3	3.3	
191	Management of dyslipidemia in patients with nonalcoholic fatty liver disease <b>2013</b> , 98-109		
190	Comment on: Novel therapeutic targets for non-alcoholic fatty liver disease. <i>Expert Opinion on Therapeutic Targets</i> , <b>2013</b> , 17, 861-2	6.4	2
189	Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients. <i>Current Medical Research and Opinion</i> , <b>2013</b> , 29, 791-2	2.5	1
188	Omega-3 fatty acids for the treatment of nonalcoholic fatty liver disease in children and adolescents. <i>Clinical Lipidology</i> , <b>2013</b> , 8, 509-512		
187	Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention. <i>Circulation Journal</i> , <b>2013</b> , 77, 1348	2.9	1
186	Cold temperature and cardiovascular mortality. <i>Circulation Journal</i> , <b>2013</b> , 77, 2846	2.9	1
185	Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?. <i>Journal of Drug Assessment</i> , <b>2013</b> , 2, 67-71	1.5	4
184	Hyperuricaemia: more than just a cause of gout?. <i>Journal of Cardiovascular Medicine</i> , <b>2013</b> , 14, 397-402	1.9	58
183	Effect of Cardio-Metabolic Risk Factors Clustering with or without Arterial Hypertension on Arterial Stiffness: A Narrative Review. <i>Diseases (Basel, Switzerland)</i> , <b>2013</b> , 1, 51-72	4.4	
182	Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Archives of Medical Science</i> , <b>2013</b> , 9, 418-26	2.9	28
181	Colesevelam: a new and improved bile acid sequestrant?. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 3115-33	3.3	14
180	Ezetimibe therapy for dyslipidemia: an update. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 3107-14	3.3	31



179	The impact of smoking on cardiovascular outcomes and comorbidities in statin-treated patients with coronary artery disease: a post hoc analysis of the GREACE study. <i>Current Vascular Pharmacology</i> , <b>2013</b> , 11, 779-84	3.3	15
178	Relation of improvement in glomerular filtration rate with atorvastatin to reductions in heart failure morbidity. <i>American Journal of Cardiology</i> , <b>2012</b> , 110, 763	3	4
177	Smoking and non-alcoholic steatohepatitis (NASH): the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) trial. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 476	13.4	4
176	Role of antihypertensive drugs in arterial de-stiffening and central pulsatile hemodynamics. <i>American Journal of Cardiovascular Drugs</i> , <b>2012</b> , 12, 143-56	4	35
175	Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. <i>Journal of Clinical Lipidology</i> , <b>2012</b> , 6, 93	4.9	1
174	The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings. <i>Archives of Medical Science</i> , <b>2012</b> , 8, 6-10	2.9	3
173	Response to Mildly decreased glomerular filtration rate is associated with poor coronary heart disease outcome <i>Clinical Cardiology</i> , <b>2012</b> , 35, 315; author reply 316-7	3.3	2
172	Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease. <i>Digestive Diseases and Sciences</i> , <b>2012</b> , 57, 1109	4	6
171	Statins in patients with renal dysfunction. <i>American Journal of Cardiology</i> , <b>2012</b> , 109, 1537	3	6
170	Long-term impact of multifactorial treatment on new-onset diabetes and related cardiovascular events in metabolic syndrome: a post hoc ATTEMPT analysis. <i>Angiology</i> , <b>2012</b> , 63, 358-66	2.1	21
169	Fibrinogen, hematocrit, and platelets in mild kidney dysfunction and the role of uric acid: an Italian male population study. <i>Clinical and Applied Thrombosis/Hemostasis</i> , <b>2012</b> , 18, 113-4	3.3	
168	Lipid lowering agents and the endothelium: an update after 4 years. <i>Current Vascular Pharmacology</i> , <b>2012</b> , 10, 33-41	3.3	16
167	Managing the combination of non-alcoholic fatty liver disease and metabolic syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 287-8; author reply 289-90	4	3
166	Should raising high-density lipoprotein cholesterol be a matter of debate?. <i>Journal of Cardiovascular Medicine</i> , <b>2012</b> , 13, 254-9	1.9	11
165	Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options. <i>Current Vascular Pharmacology</i> , <b>2012</b> , 10, 162-72	3.3	42
164	Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?. <i>Open Cardiovascular Medicine Journal</i> , <b>2012</b> , 6, 28-32	0.7	3
163	Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 Fatty Acid ethyl esters. <i>Open Cardiovascular Medicine Journal</i> , <b>2012</b> , 6, 122-5	0.7	5
162	Effects of Losartan vs. Enalapril on the Markers of Metabolic Syndrome. <i>Oman Medical Journal</i> , <b>2012</b> , 27, 177	1.4	1

161	Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2011</b> , 21, 213-21	4.5	55
160	Raised liver enzymes in patients taking statins [Authors' Reply]. <i>Lancet, The</i> , <b>2011</b> , 377, 1075-1076	4.0	1
159	Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. <i>Open Cardiovascular Medicine Journal</i> , <b>2011</b> , 5, 85-9	0.7	7
158	Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. <i>Open Cardiovascular Medicine Journal</i> , <b>2011</b> , 5, 24-34	0.7	44
157	Is there an additional benefit from coronary revascularization in diabetic patients with acute coronary syndromes or stable angina who are already on optimal medical treatment?. <i>Archives of Medical Science</i> , <b>2011</b> , 7, 1067-75	2.9	9
156	Improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. The IMPERATIVE renal analysis. <i>Archives of Medical Science</i> , <b>2011</b> , 7, 984-92	2.9	35
155	Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. <i>Archives of Medical Science</i> , <b>2011</b> , 7, 796-805	2.9	51
154	Atherosclerotic renal artery stenosis: an update on diagnosis and management. <i>Current Vascular Pharmacology</i> , <b>2011</b> , 9, 465-70	3.3	
153	Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT): a prospective-randomized study in middle aged men and women. <i>Current Vascular Pharmacology</i> , <b>2011</b> , 9, 647-57	3.3	29
152	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. <i>Current Vascular Pharmacology</i> , <b>2011</b> , 9, 531-2	3.3	91
151	Alanine aminotransferase is associated with metabolic syndrome independently of insulin resistance. <i>Circulation Journal</i> , <b>2011</b> , 75, 2027; author reply 2028	2.9	2
150	Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 302-12	6.7	104
149	Cardiovascular benefits of bariatric surgery in morbidly obese patients. <i>Obesity Reviews</i> , <b>2011</b> , 12, 515-24	0.6	66
148	Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. <i>International Journal of Clinical Practice</i> , <b>2011</b> , 65, 679-83	2.9	28
147	Impact of statins on glucose metabolism--a matter of debate. <i>American Journal of Cardiology</i> , <b>2011</b> , 107, 1866	3	4
146	Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. <i>Current Medical Research and Opinion</i> , <b>2011</b> , 27, 1659-68	2.5	36
145	Current treatment for nonalcoholic fatty liver disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2141-2; author reply 2142	4	2
144	"European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. <i>Current Vascular Pharmacology</i> , <b>2011</b> , 9, 533-7	3.3	138

143	Does metabolic syndrome influence outcome following percutaneous coronary intervention?. <i>Angiology</i> , <b>2011</b> , 62, 437-9	2.1	1
142	Hyperuricaemia and non-alcoholic fatty liver disease (NAFLD): a relationship with implications for vascular risk?. <i>Current Vascular Pharmacology</i> , <b>2011</b> , 9, 698-705	3.3	43
141	Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. <i>Open Cardiovascular Medicine Journal</i> , <b>2011</b> , 5, 226-30	0.7	3
140	Brain natriuretic peptide and the athlete's heart: a pilot study. <i>International Journal of Clinical Practice</i> , <b>2010</b> , 64, 511-7	2.9	14
139	Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 723-30	4	16
138	Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. <i>Angiology</i> , <b>2010</b> , 61, 49-57	2.1	13
137	Blood pressure levels constitute the most important determinant of the metabolic syndrome in a Mediterranean population: a discrimination analysis. <i>Metabolic Syndrome and Related Disorders</i> , <b>2010</b> , 8, 523-9	2.6	9
136	Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 713-9	2.5	78
135	Seasonal variation in the occurrence of stroke in Northern Greece: a 10 year study in 8204 patients. <i>Neurological Research</i> , <b>2010</b> , 32, 326-31	2.7	22
134	Statin loading in patients undergoing percutaneous coronary intervention for acute coronary syndromes: a new pleiotropic effect?. <i>Current Medical Research and Opinion</i> , <b>2010</b> , 26, 839-42	2.5	18
133	Statins and heart failure. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 1644-5; author reply 1646	15.1	6
132	Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2010</b> , 20, 140-6	4.5	111
131	Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. <i>Lancet, The</i> , <b>2010</b> , 376, 1916-22	4.0	459
130	Comment and reply on: Atorvastatin: safety and tolerability. Statins and polymyositis: a neglected link?. <i>Expert Opinion on Drug Safety</i> , <b>2010</b> , 9, 1005-6; author reply 1006	4.1	2
129	Atorvastatin: safety and tolerability. <i>Expert Opinion on Drug Safety</i> , <b>2010</b> , 9, 667-74	4.1	30
128	The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. <i>Current Vascular Pharmacology</i> , <b>2010</b> , 8, 792-803	3.3	11
127	Should adipokines be considered in the choice of the treatment of obesity-related health problems?. <i>Current Drug Targets</i> , <b>2010</b> , 11, 122-35	3	86
126	Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?. <i>Current Pharmaceutical Design</i> , <b>2010</b> , 16, 3939-847	3.3	8

125	The role of ankle brachial index and carotid intima-media thickness in vascular risk stratification. <i>Current Opinion in Cardiology</i> , <b>2010</b> , 25, 394-8	2.1	21
124	Aggressive statin treatment, very low serum cholesterol levels and haemorrhagic stroke: is there an association?. <i>Current Opinion in Cardiology</i> , <b>2010</b> , 25, 406-10	2.1	21
123	Myocardial perfusion scintigraphy in asymptomatic diabetic patients: a critical review. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2010</b> , 26, 336-47	7.5	12
122	Management of statin-intolerant high-risk patients. <i>Current Vascular Pharmacology</i> , <b>2010</b> , 8, 632-7	3.3	8
121	Vitamin D and cardiovascular disease: a novel agent for reducing cardiovascular risk?. <i>Current Vascular Pharmacology</i> , <b>2010</b> , 8, 720-30	3.3	41
120	Endocrine hypertension: diagnosis and management of a complex clinical entity. <i>Current Vascular Pharmacology</i> , <b>2010</b> , 8, 646-60	3.3	12
119	Homocysteine: An Emerging Cardiovascular Risk Factor that Never Really Made it~!2009-10-29~!2009-12-27~!2010-04-08~!. <i>The Open Clinical Chemistry Journal</i> , <b>2010</b> , 3, 19-24		3
118	Adrenal incidentaloma: a diagnostic challenge. <i>Hormones</i> , <b>2009</b> , 8, 163-84	3.1	52
117	Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?. <i>Angiology</i> , <b>2009</b> , 60, 74-81	2.1	6
116	Standardized arrangement for a guideline-driven treatment of the metabolic syndrome: the SAGE-METS study. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 971-80	2.5	16
115	Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2009</b> , 5, 16-7		11
114	Dyslipidemia as a risk factor for ischemic stroke. <i>Current Topics in Medicinal Chemistry</i> , <b>2009</b> , 9, 1291-7	3	55
113	Anti-inflammatory effects of fibrates: an overview. <i>Current Medicinal Chemistry</i> , <b>2009</b> , 16, 676-84	4.3	19
112	Atherosclerosis and osteoporosis: age-dependent degenerative processes or related entities?. <i>Osteoporosis International</i> , <b>2009</b> , 20, 197-207	5.3	117
111	Targeting triglycerides in secondary prevention: should we bother?. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 15-8	2.9	2
110	A comparison of the aldosterone-blocking agents eplerenone and spironolactone. <i>Clinical Cardiology</i> , <b>2009</b> , 32, 230	3.3	3
109	Implementation of strategy for the management of overt dyslipidemia: the IMPROVE-dyslipidemia study. <i>International Journal of Cardiology</i> , <b>2009</b> , 134, 322-9	3.2	23
108	Clinical review: The pathogenetic role of cortisol in the metabolic syndrome: a hypothesis. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 2692-701	5.6	445

107	Initiative for a new diabetes therapeutic approach in a Mediterranean country: the INDEED study. <i>Current Medical Research and Opinion</i> , <b>2009</b> , 25, 1931-40	2.5	9
106	Lipoprotein a: where are we now?. <i>Current Opinion in Cardiology</i> , <b>2009</b> , 24, 351-7	2.1	44
105	The role of statins for the primary and secondary prevention of coronary heart disease in women. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 1054-62	3.3	17
104	Pleiotropic effects of statins--clinical evidence. <i>Current Pharmaceutical Design</i> , <b>2009</b> , 15, 479-89	3.3	117
103	Triglycerides and vascular risk: insights from epidemiological data and interventional studies. <i>Current Drug Targets</i> , <b>2009</b> , 10, 320-7	3	23
102	Implementation of guidelines for the management of arterial hypertension. The impulsion study. <i>Open Cardiovascular Medicine Journal</i> , <b>2009</b> , 3, 26-34	0.7	13
101	Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 483-5	3	57
100	Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia. <i>American Journal of Cardiology</i> , <b>2008</b> , 101, 1679-80	3	2
99	Established and emerging vascular risk factors and the development of aortic stenosis: an opportunity for prevention?. <i>Expert Opinion on Therapeutic Targets</i> , <b>2008</b> , 12, 809-20	6.4	10
98	Do we need to consider inflammatory markers when we treat atherosclerotic disease?. <i>Atherosclerosis</i> , <b>2008</b> , 200, 1-12	3.1	63
97	Spirolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism. <i>Expert Opinion on Pharmacotherapy</i> , <b>2008</b> , 9, 509-15	4	94
96	Medical treatment as an alternative to adrenalectomy in patients with aldosterone-producing adenomas. <i>Endocrine-Related Cancer</i> , <b>2008</b> , 15, 693-700	5.7	20
95	High density lipoprotein cholesterol and statin trials. <i>Current Medicinal Chemistry</i> , <b>2008</b> , 15, 2265-70	4.3	10
94	Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 1593-9	2.5	16
93	Unusual manifestation of diarrhea-associated haemolytic uraemic syndrome in an adult. <i>Renal Failure</i> , <b>2008</b> , 30, 331-4	2.9	
92	Can We Move Forward After ADVANCE?. <i>Vascular Disease Prevention</i> , <b>2008</b> , 5, 72-74		
91	Additional effects of statins in surgical patients. <i>Annals of Surgery</i> , <b>2008</b> , 248, 140-1; author reply 141	7.8	1
90	Omega-3 fatty acids: how can they be used in secondary prevention?. <i>Current Atherosclerosis Reports</i> , <b>2008</b> , 10, 510-7	6	13

89	Statins for the prevention of first or recurrent stroke. <i>Current Vascular Pharmacology</i> , <b>2008</b> , 6, 124-33	3.3	13
88	Atherogenesis in renal patients: a model of vascular disease?. <i>Current Vascular Pharmacology</i> , <b>2008</b> , 6, 93-107	3.3	29
87	Statin Treatment May be Beneficial to Both the Kidneys and the Heart. <i>Peritoneal Dialysis International</i> , <b>2007</b> , 27, 215-216	2.8	12
86	Serum uric acid as an independent predictor of early death after acute stroke. <i>Circulation Journal</i> , <b>2007</b> , 71, 1120-7	2.9	91
85	Different definitions of the metabolic syndrome and risk of first-ever acute ischaemic non-embolic stroke in elderly subjects. <i>International Journal of Clinical Practice</i> , <b>2007</b> , 61, 545-51	2.9	25
84	Pheochromocytoma: an update on genetics and management. <i>Endocrine-Related Cancer</i> , <b>2007</b> , 14, 935-56.7		81
83	Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. <i>Lipids</i> , <b>2007</b> , 42, 999-1009	1.6	26
82	Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. <i>Nephrology Dialysis Transplantation</i> , <b>2007</b> , 22, 118-27	4.3	114
81	Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 2267-77	4	9
80	Atenolol: differences in mode of action compared with other antihypertensives. An opportunity to identify features that influence outcome?. <i>Current Pharmaceutical Design</i> , <b>2007</b> , 13, 229-39	3.3	10
79	Fish oils and vascular disease prevention: an update. <i>Current Medicinal Chemistry</i> , <b>2007</b> , 14, 2622-8	4.3	28
78	Statins and renal function. Is the compound and dose making a difference?. <i>Nephrology Dialysis Transplantation</i> , <b>2007</b> , 22, 963-4; author reply 964	4.3	14
77	The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?. <i>Expert Opinion on Therapeutic Targets</i> , <b>2007</b> , 11, 191-205	6.4	21
76	Intravenous immunoglobulins: a valuable asset in the treatment of a case of septic febrile ulceronecrotic Mucha-Habermann disease. <i>Dermatology</i> , <b>2007</b> , 215, 164-5	4.4	11
75	Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. <i>Angiology</i> , <b>2007</b> , 58, 689-97	2.1	113
74	Endothelial function, arterial stiffness and lipid lowering drugs. <i>Expert Opinion on Therapeutic Targets</i> , <b>2007</b> , 11, 1143-60	6.4	27
73	A multicentre, open study to assess the effect of individualizing starting doses of atorvastatin according to baseline LDL-C levels on achieving cholesterol targets: the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST-2) study. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 1945-56	2.5	10
72	Statins and regression of coronary atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 2197; author reply 2197	27.4	6

71	Statins exert multiple beneficial effects on patients undergoing percutaneous revascularization procedures. <i>Current Drug Targets</i> , <b>2007</b> , 8, 942-51	3	38
70	Vascular Disease and Insulin-Like Growth Factor-1. <i>Vascular Disease Prevention</i> , <b>2007</b> , 4, 306-313		
69	Identifying and attaining LDL-C goals: mission accomplished? Next target: new therapeutic options to raise HDL-C levels. <i>Current Drug Targets</i> , <b>2007</b> , 8, 483-8	3	23
68	The role of endocannabinoid system blockade in the treatment of the metabolic syndrome. <i>Journal of Clinical Pharmacology</i> , <b>2007</b> , 47, 642-52	2.9	35
67	Prevalence of vascular disease in metabolic syndrome using three proposed definitions. <i>International Journal of Cardiology</i> , <b>2007</b> , 117, 204-10	3.2	68
66	The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. <i>Atherosclerosis</i> , <b>2007</b> , 193, 428-37	3.1	82
65	Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism. <i>Nephrology Dialysis Transplantation</i> , <b>2007</b> , 22, 293	4.3	8
64	Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. <i>Open Cardiovascular Medicine Journal</i> , <b>2007</b> , 1, 8-14	0.7	22
63	The effect of cholesterol-lowering treatment on renal function. <i>American Journal of Kidney Diseases</i> , <b>2006</b> , 47, 561; author reply 562	7.4	10
62	Effect of quinapril or losartan alone and in combination on left ventricular systolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. <i>Journal of Diabetes and Its Complications</i> , <b>2006</b> , 20, 1-7	3.2	31
61	Angioedema may not be a class side-effect of the angiotensin-converting-enzyme inhibitors. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2006</b> , 99, 197-8	2.7	7
60	Definitions of metabolic syndrome: Where are we now?. <i>Current Vascular Pharmacology</i> , <b>2006</b> , 4, 185-97	3.3	31
59	Statins and solid organ transplantation. <i>Current Pharmaceutical Design</i> , <b>2006</b> , 12, 4771-83	3.3	33
58	Dyslipidaemia, hypercoagulability and the metabolic syndrome. <i>Current Vascular Pharmacology</i> , <b>2006</b> , 4, 175-83	3.3	37
57	Total serum insulin-like growth factor-1 and C-reactive protein in metabolic syndrome with or without diabetes. <i>Angiology</i> , <b>2006</b> , 57, 303-11	2.1	31
56	Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. <i>Current Medical Research and Opinion</i> , <b>2006</b> , 22, 873-83	2.5	191
55	Elevated serum uric acid levels in metabolic syndrome: an active component or an innocent bystander?. <i>Metabolism: Clinical and Experimental</i> , <b>2006</b> , 55, 1293-301	12.7	208
54	Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. <i>International Journal of Nanomedicine</i> , <b>2006</b> , 1, 129-47	7.3	42

53	Statins for non-alcoholic fatty liver disease: a new indication?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2006</b> , 24, 698-9	6.1	20
52	Dry cough as first manifestation of giant-cell arteritis. <i>Journal of the American Geriatrics Society</i> , <b>2006</b> , 54, 1957-8	5.6	7
51	Should atenolol still be recommended as first-line therapy for primary hypertension?. <i>Hellenic Journal of Cardiology</i> , <b>2006</b> , 47, 298-307	2.1	1
50	Effect of apolipoprotein E polymorphism on serum uric acid levels in healthy subjects. <i>Journal of Investigative Medicine</i> , <b>2005</b> , 53, 116-22	2.9	12
49	Bilateral renal artery stenosis and primary aldosteronism in a diabetic patient. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2005</b> , 98, 913-5	2.7	8
48	New-onset diabetes after transplantation. <i>Lancet, The</i> , <b>2005</b> , 365, 1766	4.0	3
47	Inflammatory markers and the metabolic syndrome. <i>Atherosclerosis</i> , <b>2005</b> , 183, 187-8	3.1	12
46	Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. <i>Platelets</i> , <b>2005</b> , 16, 65-71	3.6	23
45	Targeting vascular risk in patients with metabolic syndrome but without diabetes. <i>Metabolism: Clinical and Experimental</i> , <b>2005</b> , 54, 1065-74	12.7	56
44	The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. <i>Current Medical Research and Opinion</i> , <b>2005</b> , 21, 1157-95	2.5	138
43	The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. <i>Diabetes, Obesity and Metabolism</i> , <b>2005</b> , 7, 397-405	6.7	114
42	Lipid-lowering therapy in patients with peripheral arterial disease. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2005</b> , 10, 145-7	2.6	13
41	Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. <i>Hellenic Journal of Cardiology</i> , <b>2005</b> , 46, 380-6	2.1	17
40	The ORLlstat and Cardiovascular risk profile in patients with metabolic syndrome and type 2 DIAbetes (ORLICARDIA) Study. <i>Current Medical Research and Opinion</i> , <b>2004</b> , 20, 1393-401	2.5	51
39	Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , <b>2004</b> , 20, 627-37	2.5	62
38	Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. <i>Current Medical Research and Opinion</i> , <b>2004</b> , 20, 1691-1701	2.5	72
37	The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. <i>Journal of Clinical Pathology</i> , <b>2004</b> , 57, 728-34	3.9	261
36	Uric acid levels and vascular disease. <i>Current Medical Research and Opinion</i> , <b>2004</b> , 20, 951-4	2.5	51



35	The impact of serum uric acid on cardiovascular outcomes in the LIFE study. <i>Kidney International</i> , <b>2004</b> , 66, 1714-5	9.9	24
34	Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease. <i>Journal of Human Hypertension</i> , <b>2004</b> , 18, 781-8	2.6	57
33	Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. <i>American Journal of Kidney Diseases</i> , <b>2004</b> , 43, 589-99	7.4	188
32	Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , <b>2004</b> , 20, 1385-92	2.5	12
31	Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. <i>American Heart Journal</i> , <b>2004</b> , 148, 635-40	4.9	101
30	Undertreatment of dyslipidaemia in Greece. <i>Atherosclerosis</i> , <b>2004</b> , 177, 215-6	3.1	6
29	Left ventricular systolic and diastolic function in normotensive type 1 diabetic patients with or without autonomic neuropathy: a radionuclide ventriculography study. <i>Diabetes Care</i> , <b>2003</b> , 26, 1955-60	14.6	38
28	Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment. <i>Atherosclerosis</i> , <b>2003</b> , 168, 397-8	3.1	7
27	Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. <i>Current Medical Research and Opinion</i> , <b>2003</b> , 19, 22-7	2.5	60
26	Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. <i>Angiology</i> , <b>2003</b> , 54, 679-90	2.1	77
25	Statins and renal function in patients with diabetes mellitus. <i>Current Medical Research and Opinion</i> , <b>2003</b> , 19, 615-7	2.5	57
24	Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2002</b> , 9, 33-9		13
23	Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. <i>Current Medical Research and Opinion</i> , <b>2002</b> , 18, 499-502	2.5	15
22	. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>2002</b> , 9, 33-39		27
21	Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. <i>Journal of Clinical Gastroenterology</i> , <b>2002</b> , 34, 472-5	3	131
20	Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. <i>Diabetes Care</i> , <b>2002</b> , 25, 1198-202	14.6	226
19	Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. <i>Atherosclerosis</i> , <b>2002</b> , 163, 205-6	3.1	19
18	Effects of various fibrates on serum alkaline phosphatase activity. <i>Atherosclerosis</i> , <b>2002</b> , 165, 187-8	3.1	9

17	Treatment with atorvastatin to the National Cholesterol Educational Program goal versus usual care in secondary coronary heart disease prevention. The GREEK Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. <i>Current Medical Research and Opinion</i> , <b>2002</b> , 18, 220-8	2.5	424
16	Statin-fibrate combinations in patients with combined hyperlipidemia. <i>Atherosclerosis</i> , <b>2001</b> , 155, 263-4	3.1	16
15	Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. <i>Atherosclerosis</i> , <b>2001</b> , 157, 463-9	3.1	82
14	Atorvastatin Plus Pravastatin for the Treatment of Heterozygous Familial Hypercholesterolaemia -A Pilot Study. <i>Current Medical Research and Opinion</i> , <b>2001</b> , 17, 267-272	2.5	3
13	Atorvastatin Plus Pravastatin for the Treatment of Heterozygous Familial Hypercholesterolaemia - A Pilot Study. <i>Current Medical Research and Opinion</i> , <b>2001</b> , 17, 267-272	2.5	2
12	Effect of quinapril or metoprolol on circadian sympathetic and parasympathetic modulation after acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>1999</b> , 84, 1164-9	3	20
11	Effect of aldose reductase inhibition on cardiovascular reflex tests in patients with definite diabetic autonomic neuropathy over a period of 2 years. <i>Journal of Diabetes and Its Complications</i> , <b>1998</b> , 12, 201-7	3.2	13
10	The natural history of recently diagnosed autonomic neuropathy over a period of 2 years. <i>Diabetes Research and Clinical Practice</i> , <b>1998</b> , 42, 55-63	7.4	25
9	Effect of aldose reductase inhibition on heart rate variability in patients with severe or moderate diabetic autonomic neuropathy. <i>Clinical Drug Investigation</i> , <b>1998</b> , 15, 111-21	3.2	8
8	Effect of Atorvastatin versus Simvastatin on Lipid Profile and Plasma Fibrinogen in Patients with Hypercholesterolaemia: A Pilot, Randomised, Double-Blind, Dose-Titrating Study. <i>Clinical Drug Investigation</i> , <b>1998</b> , 16, 219-27	3.2	12
7	Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. <i>American Journal of Cardiology</i> , <b>1997</b> , 80, 608-13	3	132
6	Pilot Study of the Effect of the Simvastatin-Ciprofibrate Combination on Myocardial Infarction Risk Profile in Patients with Refractory Familial Combined Hyperlipidaemia. <i>Clinical Drug Investigation</i> , <b>1996</b> , 11, 196-204	3.2	1
5	Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease. <i>Coronary Artery Disease</i> , <b>1996</b> , 7, 843-50	1.4	46
4	Effect of quinapril or metoprolol on heart rate variability in post-myocardial infarction patients. <i>American Journal of Cardiology</i> , <b>1996</b> , 77, 242-6	3	46
3	Long-Term Follow-Up of a Patient with Carcinoid Disease of the Heart. <i>American Journal of Noninvasive Cardiology</i> , <b>1994</b> , 8, 171-173		
2	Effect of pravastatin in the prevention of coronary heart disease in patients with primary hypercholesterolemia. <i>Current Therapeutic Research</i> , <b>1994</b> , 55, 914-924	2.4	2
1	Combined Treatment with Pravastatin and Gemfibrozil in Patients with Refractory Familial Combined Hyperlipidaemia. <i>Drug Investigation</i> , <b>1994</b> , 7, 134-142		13